Healthcare conglomerate Danaher reported better-than-expected profits for the third quarter, thanks to strong demand for its diagnostic tests for respiratory diseases. The company's diagnostics unit, which includes COVID-19 testing kits, reported sales of $2.25 billion, beating estimates. However, its life sciences unit, which provides lab equipment and reagents, posted weaker sales of $1.71 billion. Danaher now expects a slight decline in adjusted core sales for the year.